Growth seen in nutrition, health food, supplements market

Trade Volume Signals (China, 2025)

Figures attributed to the China Chamber of Commerce for Import and Export of Medicines and Health Products indicate:

• Total industry import and export volume reached approximately $12.9 billion, a 7.1% year-on-year increase.

• Imports accounted for roughly $8.3 billion (+6.9% YoY).

• Exports stood at $4.6 billion (+7.8% YoY).

• The trade deficit widened to approximately $3.68 billion, the third consecutive year of expansion.

Industry participants at the concurrently held Healthplex Expo 2026 and Natural and Nutraceutical Products China 2026 in Shanghai framed the growth as a transition from basic supplementation toward "quality upgrades" and "precise maintenance." A representative of the Italian Trade Agency Shanghai Office stated that Chinese consumers of all ages maintain active demand for health products and that a localization strategy is being prioritized for Italian brands entering the market. Separately, the CEO of Complementary Medicines Australia stated that Australia — where health products are regulated as medicines rather than as food — generates roughly $4 billion annually, with a significant portion of demand originating from Chinese consumers.

Stated Demand Signals (Thailand)

Ipsos survey data on the Thai longevity market reports consumer-side intent rather than consumption metrics or biomarker change:

• 49% of Thai respondents expect to live to 100 years.

• 84% report wanting greater control over personal health decisions.

• 82% report actively researching health information themselves.

• 68% report making health decisions independently of a healthcare professional.

• 73% report comfort with AI-based treatment recommendations derived from personal medical history.

• 88% report believing they need to do more to care for their mental wellbeing.

• Only 19% of consumers aged 60 and above report feeling that existing products and services are designed for their demographic.

These figures describe self-reported preference and information-seeking behavior. They do not constitute pharmacokinetic or efficacy measures, and no trial linking stated preference to changes in healthspan outcomes was provided in the source material.

Logistics Throughput

A third report projects the healthcare logistics market to reach $212.84 billion by 2030. Source-level detail was not available in the materials reviewed; the projection should be treated as preliminary and not used as a basis for product-level decisions.

Analytical Verdict

Market expansion is documented; clinical efficacy is not. The datasets reviewed describe commercial throughput and survey-elicited preference — both relevant to investors and brand strategists, neither sufficient to substantiate the bioavailability, dose-response relationship, or therapeutic effect of any specific product line. Readers selecting supplements on the basis of category-level growth are advised to require, at minimum, third-party assay verification and published pharmacokinetic evidence before treating market trajectory as a proxy for personal outcome.